Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etest results

Diagnostic Microbiology and Infectious Disease

Volumn 28, Issue 4, 1997, Pages 193-200

  Jones, Ronald N ^a   Barrett, Mary S ^a   Deguchi, Takashi ^b  

^a UNIVERSITY OF IOWA   (United States)

^b GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG EFFICACY; GRAM POSITIVE COCCI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; PRIORITY JOURNAL;

AGAR; ANTI-INFECTIVE AGENTS; BACTERIOLOGICAL TECHNIQUES; CIPROFLOXACIN; CULTURE MEDIA; DRUG RESISTANCE, MICROBIAL; DRUG STABILITY; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; NEISSERIA GONORRHOEAE; SENSITIVITY AND SPECIFICITY; SPECIES SPECIFICITY;

EID: 0030867393     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00042-4     Document Type: Article

References (33)

1. Biedenbach DJ, Jones RN (1996) Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: Investigation using 510(k) review criteria, recommended by the Food and Drug Administration. J Clin Microbiol 34:3214-3217.
2. Bolmstrom A, Arvidson S, Ericsson M, Karlsson A (1988) A novel technique for direct quantification of antimicrobial susceptibility of microorganisms. In Program and Abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy (Los Angeles, CA). Washington, DC: American Society for Microbiology, (abst 1209).
3. Centers for Disease Control and Prevention (CDC) (1989) 1989 sexually transmitted diseases treatment guidelines. Morbid Mortal Weekly Rept 38:(No. SS-8).
4. Centers for Disease Control and Prevention (CDC) (1994) Decreased susceptibility of Neisseria gonorrhoeae to fluoroquinolones - Ohio and Hawaii, 1992-1994. Morbid Mortal Weekly Rept 43:325-327.
5. Centers for Disease Control and Prevention (CDC) (1995) Fluoroquinolone resistance in Neisseria gonorrhoeae - Colorado and Washington, 1995. Morbid Mortal Weekly Rept 44:761-764.
6. Clindennen TE, Echeverria P, Saengeur PS, Kees ES, Boslego JW, Wignall FS (1992) Antibiotic susceptibility survey of Neisseria gonorrhoeae in Thailand. Antimicrob Agents Chemother 36:1682-1687.
7. Deguchi T, Yasuda M, Nakano M, Ozeki S, Ezaki T, Saito I, Kawada Y (1996a) Quinolone-resistant N. gonorrhoeae: Correlation of alterations in the gyr A subunit of DNA gyrase and the par C subunit of topoisemerase IV with antimicrobial susceptibility profiles. Antimicrob Agents Chemother 40:1020-1023.
8. Deguchi T, Yasuda M, Nakano M, Ozeki S, Ezaki T, Maeda SI, Saito I, Kawada Y (1996b) Rapid detection of point mutations of the Neisseria gonorrhoeae gyr A gene associated with decreased susceptibilities to quinolones. J Clin Microbiol 34:2255-2258.
9. Deguchi T, Yasuda M, Nakano M, Ozeki S, Kanematsu E, Kawada Y, Ezaki T, Saito I (1996c) Uncommon occurrence of mutations in the gyr B gene associated with quinolone resistance in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 40:2437-2438.
10. Deguchi T, Yasuda M, Nakano M, Kanematsu E, Ozeki S, Nishino Y, Ezaki T, Maeda SI, Saito I, Kawada Y (1997) Rapid screening of point mutations of the Neisseria gonorrhoeae par C gene associated with resistance to quinolones. J Clin Microbiol 35:948-950.
11. Fuchs PC, Barry AL, Brown SD, Sewell DL (1996) In vitro activity and selection of disk content for disk-diffusion susceptibility tests with trovafloxacin. Eur J Clin Microbiol Infect Dis 15:678-652.
12. Gooding BB, Jones RN (1993) In vitro antimicrobial activity of CP-99219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother 37:349-353.
13. Hook EW, III, Pinson GB, Blalock CJ, Johnson RB (1996) Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea. Antimicrob Agents Chemother 40:1720-1721.
14. Jaffe HW, Schroeter AL, Reynolds GH, Zaidi AA, Martin Jr JE, Thayer JD (1977) Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. Antimicrob Agents Chemother 15:587-591.
15. Jones RN (1994) Preliminary interpretive criteria for in vitro susceptibility testing of CP-99,219 by dilution and disk-diffusion methods. Diagn Microbiol Infect Dis 20: 167-170.
16. Kam KM, Wong PW, Cheung MM, Ho NKY (1996) Detection of quinolone-resistant Neisseria gonorrhoeae. J Clin Microbiol 34:1462-1464.
17. Kenny GE, Cartwright FD (1996) Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob Agents Chemother 40:1048-1049.
18. Knapp JS, Hale JA, Neal SW, Wintersheid K, Rice RJ, Whittington WL (1995a) Proposed criteria for interpretation of susceptibilities of strains Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin. Antimicrob Agents Chemother 39:2442-2445.
19. Knapp JS, Neal SW, Parekh MC, Rice RJ (1995b) In vitro activity of a new fluoroquinolone, CP-99,219 against strains of Neisseria gonorrhoeae. Antimicrob Agents Chemother 39:987-989.
20. Knapp JS, Washington JA, Doyle LJ, Neal SW, Parekh MC, Rice RJ (1994) Persistence of Neisseria gonorrhoeae strains with decreased susceptibilities to ciprofloxacin and ofloxacin in Cleveland, Ohio, from 1992 through 1993. Antimicrob Agents Chemother 38:2194-2196.
21. Martin DH, Jones RB, Johnson RB (1995) A phase II study of CP-99,219 for the treatment of Chlamydia trachomatis infections. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, (abst LM 33), p. 332.
22. Moran JS, Levin WC (1995) Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 20(suppl 1):S47-S65.
23. National Committee for Clinical Laboratory Standards (NCCLS) (1997a) Performance standards for antimicrobial disk susceptibility tests: approved standard M2-A6. Villanova, PA: NCCLS.
24. National Committee for Clinical Laboratory Standards (NCCLS) (1997b) Standard methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A4. Villanova, PA: NC-CLS.
25. Pfizer Central Research (1997) Groton, CT: Data on file.
26. Tanaka M, Matsumoto T, Kobayashi I, Uchino U, Kumazawa J (1995) Emergence of in vitro resistance to fluoroquinolones in Neisseria gonorrhoeae isolated in Japan. Antimicrob Agents Chemother 39:2367-2370.
27. Tapsall JW, Lovett R, Munro R (1992) Failure of 500 mg of ciprofloxacin therapy in male urethral gonorrhoeae. Med J Aust 156:143.
28. Teng R, Liston TE, Harris SC (1996) Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother 37:955-963.
29. van der Willigen AH, van der Hoek, Wagenvoort JHT (1987) Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males. Antimicrob Agents Chemother 31:535-538.
30. Van Dyck E, Smet H, Piot P (1994) Comparison of Etest with agar dilution for antimicrobial susceptibility testing of Neisseria gonorrhoeae. J Clin Microbiol 32:1586-1588.
31. van Rijsoort-Vos JH, Stolz E, Verbrugh HA, Kluytmans JAJW (1995) In vitro activity of a new quinolone (CP-99,219) compared with ciprofloxacin, pefloxacin, azithromycin, and penicillin against Neisseria gonorrhoeae. J Antimicrob Chemother 36:215-218.
32. Wagenvoort JHT, van der Willigen AH, van Noort JA (1986) Decreased sensitivity of Neisseria gonorrhoeae to quinolone compounds. Eur J Clin Microbiol 5:685.
33. Xia M, Roberts MC, Whittington WL, Holmes KK, Knapp JS, Dillon JR, Wi T (1996) Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin: Pulsed-field gel electrophoresis typing of strains from North America, Hawaii, and the Philippines. Antimicrob Agents Chemother 40:2439-2440.